drugset / Trial / NCT00750126

Allogeneic Hematopoietic Stem Cell Transplantation

NCT00750126

Phase 2 Unknown 30 enrolled University Hospital, Clermont-Ferrand
Non-randomizedSingle-groupOpen-labelTreatment

Summary

To assess the engraftment of hematopoietic stem cells following reduced-intensity conditioning in children presenting with solid tumors or hematological malignancy by evaluating post-transplantation chimerism and hematological reconstitution. To study acute and/or chronic graft-versus-host reaction (incidence and severity) and immune reconstitution, post-transplantation To study the effectiveness of the protocol on tumor response. To study overall survival.

Timeline

Start
2007-04
Primary completion
2009-04
Completion
2009-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Busulfan Small molecule
Subject Fludarabine Small molecule
Subject Thymoglobulin Protein / enzyme biologic